GlassScriptPhysician profile
Ela Banerjee
NPI 1861856312
$7,716.69
in general payments reported to CMS, 2019-2025
33 companies · $2,774 in 2025
The $2,774 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $763 · 2022: $1,293 · 2023: $1,100 · 2024: $1,786 · 2025: $2,774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,660.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $933.37 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $887.43 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $811.68 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Amgen INC. | $734.10 | 2022-2025 | Tepezza, Evenity, Prolia |
| Dexcom, INC. | $662.99 | 2021-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $530.17 | 2021-2025 | Korlym |
| Novo Nordisk INC | $370.96 | 2021-2025 | Ozempic, Wegovy |
| Medtronic, INC. | $366.17 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Astrazeneca Pharmaceuticals LP | $355.58 | 2021-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.42 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $254.76 | 2021-2025 | |
| Sequel Med Tech, LLC | $218.62 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $211.46 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $159.21 | 2022-2024 | Omnipod |
| Abbvie INC. | $115.51 | 2023-2025 | Synthroid |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $114.01 | 2022-2025 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $104.07 | 2024-2025 | Unithroid |
| Alexion Pharmaceuticals, INC. | $80.28 | 2024-2025 | Strensiq |
| Novartis Pharmaceuticals Corporation | $70.74 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.93 | 2022-2023 | |
| Beta Bionics, INC. | $59.75 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Radius Health, INC. | $49.54 | 2024 | Tymlos |
| Soleno Therapeutics, INC. | $31.15 | 2025 | Vykat Xr |
| Exelixis INC. | $24.81 | 2023 | Cabometyx |
| Ascensia Diabetes Care US INC. | $24.13 | 2024 | |
| Sandoz INC. | $23.43 | 2025 | Jubbonti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.54 | 2022 | |
| Amarin Pharma, INC. | $21.92 | 2023 | |
| Amryt Pharma Holdings LTD | $21.05 | 2022 | |
| Ibsa Pharma INC. | $20.40 | 2024 | Licart, Tirosint |
| Neurocrine Biosciences, INC. | $19.50 | 2025 | |
| Ascendis Pharma Endocrinology INC | $17.80 | 2025 | Yorvipath |
| Hikma Pharmaceuticals USA | $17.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ela Banerjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.